A European Action Plan on Rare Diseases Is a Necessity, Not an Option – EPODIN
European Patients Organization for Dysimmune and Inflammatory Neuropathies (EPODIN) shared a post on LinkedIn:
“A European Action Plan on Rare Diseases: a necessity, not an option
Between 27 and 36 million people in the European Union live with a rare disease.
95% of rare diseases lack of approved therapy.
Diagnostic delays often last years.
- Access to care and therapies still depends heavily on where a patient lives.
- In this context, the European Parliament is working on a European Action Plan on Rare Diseases.
Why does the European level matter?
- Because rare diseases are, by definition, scattered.
- Because expertise is limited and unevenly distributed.
- Because data remain fragmented.
- Because purely national responses have clear limitations.
European added value is not theoretical. It already exists.
The European Reference Networks (ERNs) are a concrete example:
- More than 1,600 centres of expertise connected across Europe
- Virtual cross-border consultations for complex cases
- Shared clinical expertise
- Reduced duplication and improved access to specialised care
ERNs demonstrate that when Europe coordinates and structures expertise, patients benefit from more equitable and timely access to highly specialised care.
However, a future Action Plan will only succeed if patient organisations are placed at the heart of the system.
They are not just stakeholders. They are:
- Identifiers of unmet needs
- Holders of lived expertise
- Partners in research and data generation
- Advocates for equity and non-discrimination
A European rare disease framework is not only about technical coordination.
It is about responding to citizen-driven public health and equity challenges.
Any Action Plan must first and foremost:
- Address transversal unmet needs
- Reduce territorial and social inequalities
- Strengthen structures that already demonstrate clear added value
- Embed the patient voice structurally, not symbolically
Rare diseases are a medical challenge.
They are also a test for Europe’s commitment to health equity and social cohesion.
The response must be collective, coordinated and ambitious.”
Stay updated with Hemostasis Today.
-
Jul 12, 2026, 08:50Where the Hemophilia Community Comes Together at ISTH 2026 – EAHAD
-
Jul 12, 2026, 08:2210 Posts Not To Miss from ISTH 2026, Part 1
-
Jul 12, 2026, 07:58Brian O Mahony: Could NXT-007 Minimize the Need for Perioperative FVIII
-
Jul 12, 2026, 07:50Shayan Mohammadmoradi: Connecting the Next Generation of Hemostasis Researchers at ISTH 2026
-
Jul 12, 2026, 07:42Alexandra Yakusheva: ThrombInnov Debuts at ISTH 2026 with a Focus on Translational Research
-
Jul 12, 2026, 07:34Wolfgang Miesbach: ISTH 2026 Explores the Next Generation of APS Diagnostics
-
Jul 12, 2026, 07:28Sara Zalghout: ISTH 2026 Highlights Progress in Thromboinflammation Research
-
Jul 12, 2026, 07:13Ekaterina Balaian: Finding Healing Through Art at ISTH 2026
-
Jul 12, 2026, 06:59Maaike Sybil Jongen: Flow Cytometry for Platelet Phenotyping at ISTH 2026